With its impressive achievements, Molsentech (Molecular Sensoring Technology Co., Ltd.) got selected by the TTA Global Challenge sponsored by Taiwan's Ministry of Science and Technology to participate in US BIO 2022, poised to leverage its introduction to the US market as a stepping stone to leap further into the global stage.

The startup has successfully launched an electrical based detection system employing ultra-high sensitivity biomedical detection technology that can be applied in various disease detection from an early stage including SARS-CoV-2.

Founded in Taiwan, the world's leading semiconductor hub, Molsentech's pivotal breakthrough was its development of a 100% semiconductor-based biosensor platform which offers valuable application in the field of healthcare for disease detection. The core technology is called Bio-FET which allows biosensors to analyse liquid-form samples by measuring the electrical signal changes caused by the interactions between detection targets and bio probes modified on the surface of biosensors.

Patented in the United States, Taiwan, and China, the technology overcomes one of the biggest challenges in the industry when dealing with samples in liquid forms, interpreting the samples in 5 minutes to give immediate results.

As its technology is now available for commercial use on a global scale, Molsentech intends to further expand its presence in the global market, first into the United States, a country with the most advanced healthcare ecosystem to bring its technology and products to the next level.